Solid Biosciences (SLDB) Cash from Financing Activities (2017 - 2026)
Quarterly results put Cash from Financing Activities at $239.0 million for Q1 2026, up 25.98% from a year ago — trailing twelve months through Mar 2026 was $243.7 million (up 18.94% YoY), and the annual figure for FY2025 was $194.4 million, up 58.81%.
Solid Biosciences has reported Cash from Financing Activities over the past 9 years, most recently at $239.0 million for Q1 2026.
- Cash from Financing Activities reached $239.0 million in Q1 2026 per SLDB's latest filing, up from $5.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $239.0 million in Q1 2026 and bottomed at -$1.6 million in Q2 2025.
- Median Cash from Financing Activities over the past 5 years was $4.1 million (2024), compared with a mean of $45.1 million.
- Peak annual rise in Cash from Financing Activities hit 113137.88% in 2022, while the deepest fall reached 133.33% in 2022.
- Over 5 years, Cash from Financing Activities stood at $74.7 million in 2022, then crashed by 99.32% to $505000.0 in 2023, then soared by 1274.26% to $6.9 million in 2024, then decreased by 25.89% to $5.1 million in 2025, then skyrocketed by 4547.62% to $239.0 million in 2026.
- Business Quant data shows Cash from Financing Activities for SLDB at $239.0 million in Q1 2026, $5.1 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | 239.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 239.03 Mn |
| Mar 31, 2026 | 239.03 Mn |
| Dec 31, 2025 | 5.14 Mn |
| Dec 31, 2025 | 5.14 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | -1.60 Mn |
| Jun 30, 2025 | -1.60 Mn |
| Mar 31, 2025 | 189.73 Mn |
| Mar 31, 2025 | 189.73 Mn |
| Dec 31, 2024 | 6.94 Mn |
| Dec 31, 2024 | 6.94 Mn |
| Sep 30, 2024 | 3.26 Mn |
| Sep 30, 2024 | 3.26 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 5.00 Mn |
| Mar 31, 2024 | 107.24 Mn |
| Mar 31, 2024 | 107.24 Mn |
| Dec 31, 2023 | 505,000.00 |
| Dec 31, 2023 | 505,000.00 |
| Dec 31, 2022 | 74.74 Mn |
| Dec 31, 2022 | 74.74 Mn |
| Sep 30, 2022 | -1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Mar 31, 2022 | 22,000.00 |
| Mar 31, 2022 | 22,000.00 |
| Dec 31, 2021 | 66,000.00 |
| Dec 31, 2021 | 66,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | -238,000.00 |
| Jun 30, 2021 | -238,000.00 |
| Mar 31, 2021 | 135.15 Mn |
| Mar 31, 2021 | 135.15 Mn |
| Dec 31, 2019 | -287,000.00 |
| Dec 31, 2019 | -287,000.00 |
| Dec 31, 2018 | -13,000.00 |
| Dec 31, 2018 | -13,000.00 |
| Jun 30, 2018 | -193,000.00 |
| Jun 30, 2018 | -193,000.00 |
| Mar 31, 2018 | 131.71 Mn |
| Mar 31, 2018 | 131.71 Mn |
| Dec 31, 2017 | 53.76 Mn |
| Dec 31, 2017 | 53.76 Mn |
| Sep 30, 2017 | -943,000.00 |
| Sep 30, 2017 | -943,000.00 |
| Jun 30, 2017 | -558,000.00 |
| Jun 30, 2017 | -558,000.00 |
| Mar 31, 2017 | 24.82 Mn |
| Mar 31, 2017 | 24.82 Mn |